Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

KALAMAZOO, Mich. — Those who are recovering from addiction now have a new lifeline in Kalamazoo. Reach Sober Living has just ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Organizations join forces to create more mental health services in New Orleans, aided by a grant from the United Way.

“People would sit in my chair, and any hairdresser… knows, that’s like therapy. And people are heavy, they’re carrying around ...

Kennedy is Trump’s pick for health secretary, but he has a history of spreading misinformation about a range of issues.